APA (7th ed.) Citation
(2026). A cost-effectiveness analysis comparing pembrolizumab combined with chemotherapy versus chemotherapy alone for advanced biliary tract cancer: US and China perspectives. PLOS ONE.
Chicago Style (17th ed.) Citation
"A Cost-effectiveness Analysis Comparing Pembrolizumab Combined with Chemotherapy Versus Chemotherapy Alone for Advanced Biliary Tract Cancer: US and China Perspectives." PLOS ONE 2026.
MLA (9th ed.) Citation
"A Cost-effectiveness Analysis Comparing Pembrolizumab Combined with Chemotherapy Versus Chemotherapy Alone for Advanced Biliary Tract Cancer: US and China Perspectives." PLOS ONE, 2026.
Warning: These citations may not always be 100% accurate.